Novel Molecule May Rival GLP-1s for Diabetes and Obesity Treatment
The popularity of GLP-1-based drugs is testament to the importance of a drug that increases fat burning and lowers blood sugar. Now, a new drug—taken in the form of a tablet—offers the outcome of GLP-1-based drugs (which are administered via injection) but with a different mechanism of action. GLP-1 drugs affect hunger via signals between […]
STAT+: Pharmalittle: We’re reading about Novo ending Hims deal, FDA transparency, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But what can you do? There is no pause button to stop the world, such as it is, from spinning. So this means one thing: time […]
Corxel, Sciwind post GLP-1 data as China’s obesity push gathers pace
The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with Corxel Pharmaceuticals and Sciwind Biosciences among the companies to share data at the event.
Shiru invites brands to harness its AI platform to explore ‘natural’ GLP-1 activation: ‘The opportunity is immense’
Shiru, a startup deploying AI to aid in ingredient discovery, is inviting food companies to use its platform to explore ingredients that naturally stimulate production of GLP-1, a gut hormone associated with appetite regulation. The new GLP-1 Innovation Alliance, an industry consortium that invites “Fortune 500 CPG companies and emerging brands to collaborate as equals” […]
China’s GLP-1 Shows Similar Weight Loss to Wegovy
Overweight patients given an experimental weight loss drug being developed by China’s Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line… Reuters Health Information
STAT+: Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs
Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.” Earlier this year Novo launched a direct-to-consumer website that sells Wegovy at a lower price to patients who are paying on their own without insurance. […]
Med14 phosphorylation shapes genomic response to GLP-1 Agonist
Under feeding conditions, release of glucagon-like peptide (GLP-1) from intestinal L cells promotes insulin secretion and pancreatic beta cell viability. Binding of GLP-1 to its cognate receptor on the beta cell surface results in induction of the cAMP signaling pathway, leading to the protein kinase A (PKA) mediated phosphorylation of CREB and induction of CREB […]
Federal judge upholds FDA’s decision to remove GLP-1 drugs from shortage list
(NaturalNews) On June 18, a federal judge ruled that the Food and Drug Administration (FDA) acted lawfully when it removed semaglutide (Ozempic, Wegovy) from th…
Hims & Hers Health Crashes After Novo Nukes GLP-1 Partnership Over “Illegal Mass Compounding” Scheme
Hims & Hers Health Crashes After Novo Nukes GLP-1 Partnership Over “Illegal Mass Compounding” Scheme Shares of Hims & Hers Health crashed in premarket trading after Novo Nordisk terminated its GLP-1 partnership with the telehealth firm, citing violations of federal law related to mass sales of compounded drugs disguised as “personalized” treatments, along with deceptive […]
#ADA25: Lilly’s bimagrumab boosts weight and fat loss when added to Novo’s Wegovy
Eli Lilly’s muscle-boosting drug allowed obese patients who are taking Novo Nordisk’s Wegovy to retain almost all of their lean tissue, according to data presented Monday. The data are from a Phase 2b trial called …